This latest twist during the Lykos Therapeutics saga threatens a major overhaul of the company’s system and course, with Musk ally and billionaire investor Antonio Gracias showing up to choose to consider the company back toward its nonprofit drug improvement roots and a more Doblinite philosophy.By signing up to the copyright Spotlight publicati